Search - tctmd.com

Displaying 401 - 420 of 1423

Sort: Relevancy | Date

Presentation TCT 2017

RAPID Program: Industry View

Presenter: Schuyler Jones, Hiroyoshi Yokoi, Robert Thatcher

October 30, 2017

Presentation TCT 2017

Futuristic and Novel #2: Using Artificial Intelligence (Machine Learning) to Direct Acquisition and Interpretation of Echocardiograms Improving Access and Quality of Valve Disease Diagnosis

Presenter: Robert O. Bonow, Michael J. Mack, Randolph P. Martin

October 30, 2017

Presentation TCT 2017

WATCHMAN: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy

October 30, 2017

Presentation TCT 2017

RAPID Program: Academic View

Presenter: Schuyler Jones, Hiroyoshi Yokoi

October 30, 2017

Presentation TCT 2017

First Results From the SPYRAL Hypertension Program (OFF-MED Study)

Presenter: Michael Böhm, Thomas F. Luscher

October 30, 2017

Presentation TCT 2017

RAPID Program: PMDA View

Presenter: Schuyler Jones, Hiroyoshi Yokoi, Yoshimasa Yokoyama

October 30, 2017

Presentation TCT 2017

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

Presenter: Robert O. Bonow, Michael J. Mack, Maximilian Y Emmert

October 30, 2017

Presentation TCT 2017

Perspectives on Current Trials in Renal Denervation: Evolution of Design, Endpoints, and Objectives

Presenter: Michael Böhm, Thomas F. Luscher, Felix Mahfoud

October 30, 2017

Presentation TCT 2017

Registry Assessment of Peripheral Interventional Devices (RAPID) Program

Presenter: Schuyler Jones, Hiroyoshi Yokoi, Eleni Whatley

October 30, 2017

Presentation TCT 2017

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, Kurt Huber

October 30, 2017

Presentation TCT 2017

Potential Interventions for Hypertensive Patients With HFpEF

Presenter: Mark C. Bates, Bernard J. Gersh, William T. Abraham

October 30, 2017

Presentation TCT 2017

From Traditional Society Guidelines to Rapid Communications (e.g. BMJ WikiRecs): Evidence Development, Clinical Practice Standards, and Treatment Recommendations

Presenter: Robert O. Bonow, Michael J. Mack, David Hildick-Smith

October 30, 2017

Presentation TCT 2017

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of Women

Presenter: Wayne B. Batchelor, George A. Mensah, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Presenter: Robert A. Byrne, Gregg W. Stone, Aaron V. Kaplan

October 30, 2017

Presentation TCT 2017

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of African American/Latina Populations

Presenter: Wayne B. Batchelor, George A. Mensah

October 30, 2017

Presentation TCT 2017

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: SCAI

Presenter: Wayne B. Batchelor, George A. Mensah, Cindy L. Grines

October 30, 2017

Presentation TCT 2017

When Should Coronary Disease Be Suspected and Worked Up in Hypertension?

Presenter: Mark C. Bates, Bernard J. Gersh, Farrell O. Mendelsohn

October 30, 2017

Presentation TCT 2017

Aortic Stenosis Population Oddities Who are the Patients Not Being Diagnosed or Treated?

Presenter: Robert O. Bonow, Michael J. Mack, Maurice E. Sarano

October 30, 2017

Advertisement

RAPID Program: Industry View

Futuristic and Novel #2: Using Artificial Intelligence (Machine Learning) to Direct Acquisition and Interpretation of Echocardiograms Improving Access and Quality of Valve Disease Diagnosis

WATCHMAN: Data Synthesis and Ongoing Trials

RAPID Program: Academic View

First Results From the SPYRAL Hypertension Program (OFF-MED Study)

RAPID Program: PMDA View

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Futuristic and Novel #1: The Promise of Tissue Engineered Bioprosthetic Heart Valves (Both Surgical and Transcatheter) is Within Reach

Perspectives on Current Trials in Renal Denervation: Evolution of Design, Endpoints, and Objectives

Registry Assessment of Peripheral Interventional Devices (RAPID) Program

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Potential Interventions for Hypertensive Patients With HFpEF

From Traditional Society Guidelines to Rapid Communications (e.g. BMJ WikiRecs): Evidence Development, Clinical Practice Standards, and Treatment Recommendations

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of Women

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of African American/Latina Populations

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: SCAI

When Should Coronary Disease Be Suspected and Worked Up in Hypertension?

Aortic Stenosis Population Oddities Who are the Patients Not Being Diagnosed or Treated?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content